Setterwalls has advised Iconovo in connection with a directed share issue and a rights issue

Iconovo develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The new share issues strengthen the company’s financial position and facilitate continued project and licensing activities.

Through the directed share issue, which was made to the company’s existing principal owners, Färna Invest and FSG, and the rights issue, which was subscribed to approximately 97.43 percent, Iconovo receives issue proceeds of approximately SEK 50 million before issue costs.